What is the difference between Kisspeptin-10 and Tesamorelin?

Kisspeptin-10: Kisspeptin-10 is the biologically active 10-amino acid C-terminal fragment of kisspeptin, a neuropeptide that acts as the master regulator of the hypothalamic-pituitary-gonadal (HPG) axis. By activating KISS1R (GPR54) in the hypothalamus, it triggers pulsatile GnRH release, which drives LH, FSH, and downstream testosterone and estrogen production. It is the upstream signal that 'turns on' the reproductive axis — with research applications spanning fertility, hypogonadism, post-cycle therapy support, and age-related hormonal decline. Tesamorelin: Tesamorelin is an FDA-approved synthetic analog of growth hormone-releasing hormone (GHRH). Approved in 2010 as Egrifta, it is the only GHRH peptide with an approved clinical indication — reduction of excess visceral abdominal fat in people with HIV-associated lipodystrophy. It has the most robust human trial evidence of any growth hormone secretagogue, including dedicated studies on visceral fat and liver fat. Both are in the Performance & Growth Hormone category but differ in mechanism, dosing, and research evidence — see the full comparison.

Can you take Kisspeptin-10 and Tesamorelin together?

There is no specific, well-documented interaction rule for combining Kisspeptin-10 and Tesamorelin in the aggregated research reviewed. Combining peptides should only be considered under professional supervision. This is not medical advice.

Which is better researched, Kisspeptin-10 or Tesamorelin?

Kisspeptin-10 is currently fda-approved and Tesamorelin is fda-approved. "Better researched" depends on your research goal — review each profile's cited sources.

Performance & Growth Hormone · Comparison

Kisspeptin-10 vs Tesamorelin

A neutral, side-by-side comparison of two performance & growth hormone peptides — their mechanisms, dosing ranges, administration routes, side effects, and research evidence. For research and educational purposes only.

Kisspeptin-10

FDA-approved

Kisspeptin-10 is the biologically active 10-amino acid C-terminal fragment of kisspeptin, a neuropeptide that acts as the master regulator of the hypothalamic-pituitary-gonadal (HPG) axis. By activating KISS1R (GPR54) in the hypothalamus, it triggers pulsatile GnRH release, which drives LH, FSH, and downstream testosterone and estrogen production. It is the upstream signal that 'turns on' the reproductive axis — with research applications spanning fertility, hypogonadism, post-cycle therapy support, and age-related hormonal decline.

Full profile

Tesamorelin

FDA-approved

Tesamorelin is an FDA-approved synthetic analog of growth hormone-releasing hormone (GHRH). Approved in 2010 as Egrifta, it is the only GHRH peptide with an approved clinical indication — reduction of excess visceral abdominal fat in people with HIV-associated lipodystrophy. It has the most robust human trial evidence of any growth hormone secretagogue, including dedicated studies on visceral fat and liver fat.

Full profile

	Kisspeptin-10	Tesamorelin
Category	Performance & Growth Hormone	Performance & Growth Hormone
Also known as	KP-10, Metastin(112-121), KISS1R agonist	Egrifta, Egrifta SV, TH9507, GHRH analog
Evidence	FDA-approved	FDA-approved
Dosing range	50mcg–250mcg mcg, 1–2x daily (pulsatile administration is important — avoid continuous infusion)	1.28mg–2mg mg, once daily (subcutaneous)
Administration	Subcutaneous injection, Intranasal, Intravenous (clinical studies — produces most reliable LH pulses)	Subcutaneous injection (abdomen, with site rotation)
Key side effects	Generally well-tolerated in clinical trials, Nausea (mild, uncommon), Potential for over-stimulation of the HPG axis at high doses (rarely significant), Theoretical desensitization with continuous (non-pulsatile) dosing	Injection site reactions (erythema, pruritus), Peripheral edema, Arthralgia (joint pain), Myalgia
Cited sources	3 references	5 references

Key differences

Administration: Kisspeptin-10 — Subcutaneous injection, Intranasal, Intravenous (clinical studies — produces most reliable LH pulses); Tesamorelin — Subcutaneous injection (abdomen, with site rotation).
Dosing units differ: Kisspeptin-10 is dosed in mcg, Tesamorelin in mg — they operate at different scales.
Frequency: Kisspeptin-10 is typically 1–2x daily (pulsatile administration is important — avoid continuous infusion); Tesamorelin is once daily (subcutaneous).
Research depth: this profile cites 3 sources for Kisspeptin-10 vs 5 for Tesamorelin.

How each works

Kisspeptin-10

Kisspeptin neurons in the arcuate nucleus form the pulse generator for GnRH secretion — without kisspeptin signaling, reproductive function ceases. Human clinical trials confirm that IV kisspeptin-10 produces rapid, dose-dependent LH pulses in both males and females, restoring hormonal function in hypogonadotropic hypogonadism. Kisspeptin-54 (the longer form) has been studied in human fertility treatments with successful outcomes. Unlike direct LH/FSH administration, kisspeptin works upstream at the hypothalamus, preserving the natural pulsatile release pattern and avoiding receptor desensitization associated with continuous GnRH agonists.

Tesamorelin

Tesamorelin stimulates pulsatile growth hormone (GH) release from the pituitary, raising serum IGF-1 and preferentially reducing visceral adipose tissue (VAT). FDA-registration trials (Falutz et al., NEJM 2007; JAIDS 2010) showed ~15% VAT reduction versus placebo over 26 weeks. Later randomized trials (Stanley et al., JAMA 2014; Lancet HIV 2019) extended the evidence to liver fat, showing meaningful reductions in hepatic fat fraction and attenuated fibrosis progression in HIV-associated NAFLD.

Read the full Kisspeptin-10 profile Read the full Tesamorelin profile

This comparison aggregates public research and structured profile data for informational purposes only. It is not medical advice and does not recommend either compound for human use. Consult a qualified healthcare provider before considering any peptide.